Healthcare [ 5/13 ] | Biotechnology [ 50/159 ]
NYSE | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | 0 Decreased by -100% | 0.78 Decreased by -100% |
| Jan 31, 24 | 4.91 Decreased by -18.44% | 4.48 Increased by +9.6% |
| Nov 2, 23 | 5 Decreased by -21.14% | 5 |
| Sep 11, 23 | 17.41 Increased by +197.1% | 8.81 Increased by +97.62% |
| May 4, 23 | 8.78 Increased by +41.16% | 8.64 Increased by +1.62% |
| Feb 1, 23 | 6.02 Increased by +26.47% | 5.83 Increased by +3.26% |
| Nov 2, 22 | 6.34 Increased by +20.3% | 6.3 Increased by +0.63% |
| Aug 3, 22 | 5.86 Increased by +11.41% | 5.61 Increased by +4.46% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 65.86 B Increased by +36.95% | 21.96 B Increased by +61.59% | Increased by +33.35% Increased by +17.99% |
| Sep 30, 23 | 58.73 B Increased by +28.89% | 22.48 B Increased by +56.04% | Increased by +38.27% Increased by +21.06% |
| Jun 30, 23 | 54.3 B Increased by +31.59% | 19.43 B Increased by +45.88% | Increased by +35.78% Increased by +10.86% |
| Mar 31, 23 | 53.37 B Increased by +26.97% | 19.81 B Increased by +39.44% | Increased by +37.13% Increased by +9.82% |
| Dec 31, 22 | 48.09 B Increased by +25.46% | 13.59 B Increased by +24.79% | Increased by +28.26% Decreased by -0.53% |
| Sep 30, 22 | 45.57 B Increased by +27.92% | 14.4 B Increased by +18.86% | Increased by +31.61% Decreased by -7.08% |
| Jun 30, 22 | 41.27 B Increased by +24.89% | 13.32 B Increased by +9.86% | Increased by +32.27% Decreased by -12.04% |
| Mar 31, 22 | 42.03 B Increased by +24.34% | 14.21 B Increased by +12.57% | Increased by +33.81% Decreased by -9.46% |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.